Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1492 Views
-
Last post by NHE
-
- 0 Replies
- 831 Views
-
Last post by NHE
-
- 0 Replies
- 2396 Views
-
Last post by frodo
-
- 0 Replies
- 1111 Views
-
Last post by NHE
-
- 1 Replies
- 1102 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1391 Views
-
Last post by frodo
-
- 0 Replies
- 1582 Views
-
Last post by NHE
-
- 0 Replies
- 2142 Views
-
Last post by vesta
-
- 0 Replies
- 1645 Views
-
Last post by frodo